bluebird bio Newsroom

J.P. Morgan Maintains Bluebird Bio(BLUE.US) With Hold Rating

Futu NewsOct 10 19:31

Bluebird Bio's Restructuring Efforts and Financial Outlook: A Cautious Hold Rating

TipRanksSep 28 01:18

Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo

Dow JonesSep 26 00:46

Bluebird Bio Analyst Ratings

BenzingaSep 26 00:37

Wells Fargo Maintains Bluebird Bio(BLUE.US) With Hold Rating, Cuts Target Price to $2

Futu NewsSep 25 18:32

Maintaining Hold on Bluebird Bio: Balancing LYFGENIA's Promise Against Financial and Operational Hurdles

TipRanksSep 25 17:49

Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $4

Futu NewsSep 25 17:33

Analysts Are Bullish on Top Healthcare Stocks: Bluebird Bio (BLUE), Immunic (IMUX)

TipRanksSep 25 17:07

William Blair Maintains Bluebird Bio(BLUE.US) With Hold Rating

Futu NewsSep 24 23:32

William Blair Reaffirms Their Hold Rating on Bluebird Bio (BLUE)

TipRanksSep 24 23:28

Bluebird Bio Analyst Ratings

BenzingaSep 16 20:27

J.P. Morgan Maintains Bluebird Bio(BLUE.US) With Hold Rating

Futu NewsAug 19 20:31

Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), ImmunityBio (IBRX) and Neurocrine (NBIX)

TipRanksAug 19 20:16

What 4 Analyst Ratings Have To Say About Bluebird Bio

BenzingaAug 16 04:02

Bluebird Bio Price Target Cut to $3.00/Share From $4.00 by B of A Securities

Dow JonesAug 16 01:28

RBC Capital Maintains Bluebird Bio(BLUE.US) With Hold Rating, Maintains Target Price $4

Futu NewsAug 15 23:32

Barclays Maintains Overweight on Bluebird Bio, Lowers Price Target to $4

BenzingaAug 15 21:53

BofA Securities Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $3

Futu NewsAug 15 21:31

A Quick Look at Today's Ratings for Bluebird Bio(BLUE.US), With a Forecast Between $3 to $4

Futu NewsAug 15 21:01

Bluebird Bio Analyst Ratings

BenzingaAug 15 18:54